Anzeige
Mehr »
Mittwoch, 13.05.2026 - Börsentäglich über 12.000 News
Kann Inspiration Mining die nächste 1.000 % Chance werden? Das Bohrprogramm startet in wenigen Tagen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DTRX | ISIN: US92854B1098 | Ticker-Symbol: U5P
Tradegate
11.05.26 | 19:28
1,010 Euro
+3,59 % +0,035
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
VIVANI MEDICAL INC Chart 1 Jahr
5-Tage-Chart
VIVANI MEDICAL INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,0101,02012.05.
0,9501,00012.05.

Aktuelle News zur VIVANI MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
Leser Medien
VIVANI MEDICAL Aktie jetzt für 0€ handeln
27.03.Vivani completes first-in-human study of GLP-1 implant2
26.03.Vivani Medical, Inc. - 8-K, Current Report1
26.03.Vivani Medical, Inc. - 10-K, Annual Report1
26.03.Vivani Medical GAAP EPS of -$0.43 misses by $0.012
26.03.Vivani Medical, Inc.: Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update632Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under...
► Artikel lesen
29.01.Vivani Medical, Inc.: Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026318Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology Cortigent is the only company to have obtained FDA approval of a device providing artificial...
► Artikel lesen
27.01.Vivani Medical, Inc. Announces Closing of Common Stock Offering4
27.01.Vivani Medical, Inc. - 8-K, Current Report3
26.01.Vivani Medical prices common stock offering1
26.01.Vivani Prices Common Stock Offering At $1.48/Shr-
26.01.Vivani Medical prices $4.5 million stock offering at $1.48 per share3
26.01.Vivani Medical, Inc. Announces Pricing of Common Stock Offering1
22.01.Vivani Medical, Inc.: Vivani Subsidiary Cortigent to Present Orion System's Advanced Brain Implant Technology in Poster Session at NANS 20261
13.11.25Vivani Medical, Inc.: Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results260Company plans to initiate Phase 1 clinical study of semaglutide implant for chronic weight management in the first half of 2026 and parallel investments in studies to enable rapid initiation of Phase...
► Artikel lesen
03.10.25Vivani Medical, Inc.: Vivani Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-Off375ALAMEDA, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting...
► Artikel lesen
17.09.25Vivani Medical, Inc.: Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders293Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to have obtained FDA approval of a device providing artificial vision...
► Artikel lesen
13.08.25Vivani Medical, Inc.: Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results263Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clinical...
► Artikel lesen
05.08.25Vivani Medical, Inc.: Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 ...238LIBERATE-1, the first-in-human application of Vivani's NanoPortalTM implant technology, showed a positive safety and tolerability profile, along with encouraging performance data for NPM-115 that...
► Artikel lesen
29.05.25Vivani Medical, Inc.: Vivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders236Transaction is anticipated to be completed in third quarter 2025 Planned Cortigent Nasdaq listing intended to drive value for Vivani and Cortigent stockholders Cortigent is developing the Orion® Visual...
► Artikel lesen
13.05.25Vivani Medical, Inc.: Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results296All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in the on-going LIBERATE-1 study in obese or overweight individuals; top-line...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1